# Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

> **NCT00526045** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 117 (actual)

## Conditions studied

- Breast Cancer
- Hematologic Neoplasms

## Interventions

- **DRUG:** AUY922 2 mg/m2

## Key facts

- **NCT ID:** NCT00526045
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00526045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00526045, "Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00526045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*